Royal Bank of Canada
SGMT icon

Royal Bank of Canada’s Sagimet Biosciences SGMT Stock Holding History

Royal Bank of Canada’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29K Buy
5,576
+649
+13% +$3.62K ﹤0.01% 5743
2025
Q4 		$29K Buy
4,927
+4,391
+819% +$31.5K ﹤0.01% 5848
2025
Q3 		$3K Sell
536
-351
-40% -$2.85K ﹤0.01% 6821
2025
Q2 		$7K Buy
887
+387
+77% +$1.63K ﹤0.01% 6575
2025
Q1 		$2K Buy
+500
New +$2.1K ﹤0.01% 6589
2024
Q3 		– Sell
-452
Closed -$2K – 7376
2024
Q2 		$2K Sell
452
-2,579
-85% -$11.8K ﹤0.01% 6751
2024
Q1 		$17K Buy
3,031
+1,370
+82% +$9.84K ﹤0.01% 5986
2023
Q4 		$9K Buy
1,661
+790
+91% +$3.73K ﹤0.01% 6531
2023
Q3 		$8K Buy
+871
New +$11.6K ﹤0.01% 6499

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royal Bank of Canada's SGMT Position: Q1 2026 in Review

Royal Bank of Canada increased its Sagimet Biosciences (SGMT) stake by 13% in Q1 2026, buying an estimated $3.62K and bringing the position to 5,576 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #5743.

Royal Bank of Canada first reported a position in SGMT in Q3 2023 and has held it in 9 quarters since. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Royal Bank of Canada held 5,576 shares of Sagimet Biosciences worth $29K as of Q1 2026.
  • Royal Bank of Canada bought 649 Sagimet Biosciences shares in Q1 2026, an estimated $3.62K.
  • Sagimet Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5743 holding.
  • Royal Bank of Canada first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 9 quarters since.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.